Today, Achillion Pharmaceuticals, Inc. announced new trial results, which demonstrated that its experimental hepatitis C drug, when used in combination with Gilead Sciences Inc’s Sovaldi, eliminated the virus after just six weeks of therapy. The company provided an update on interim results from the ongoing interferon-free, ribavirin-free, Phase II …